Valuation : United Therapeutics Corporation

Market Cap 22.11B 19.05B 17.86B 16.31B 30.72B 2,113B 30.81B 212B 82.68B 1,067B 83.01B 81.2B 3,537B P/E 2026 *
19.8x
P/E 2027 * 18x
Enterprise Value 19.14B 16.49B 15.46B 14.11B 26.59B 1,829B 26.67B 183B 71.57B 923B 71.85B 70.28B 3,061B EV / Sales 2026 *
6.1x
EV / Sales 2027 * 5.32x
Free-Float
53.72%
Yield 2026 *
-
Yield 2027 * -
1 day-2.36%
1 week+0.46%
Current month-0.43%
1 month-1.56%
3 months-8.30%
6 months+2.29%
Current year+5.79%
1 week 508.15
Extreme 508.1541
531.76
1 month 490.8
Extreme 490.8
541.03
Current year 455.63
Extreme 455.63
609.35
1 year 375.61
Extreme 375.61
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 26/06/1996
President 54 26/06/2016
Director of Finance/CFO 58 13/03/2015
Director TitleAgeSince
Director/Board Member 78 01/01/2002
Chairman 71 26/06/1996
Director/Board Member 92 01/01/2002
Date Insider Type Main position Quantity % Market Cap.
8/26/26 A Fiscal year

Chief Executive Officer

28,500 0.0671%
8/25/26 A Fiscal year

Chief Executive Officer

28,500 0.0671%
8/24/26 A Fiscal year

Chief Executive Officer

28,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%+0.46%+67.77%+128.07% 22.11B
-0.13%-6.44%+60.47%+112.05% 1,047B
+0.85%-0.81%+52.77%+63.15% 646B
-1.03%-3.58%+22.87%+73.29% 451B
-1.46%-4.50%+37.43%+38.41% 355B
-0.72%-2.89%+21.86%+36.79% 291B
-1.19%-2.21%+1.35%+12.29% 252B
-1.05%-1.57%+51.40%+68.55% 234B
+0.08%-1.78%-17.64%-54.29% 203B
-2.14%-0.30%+29.42%+89.10% 181B
Average -0.93%-2.36%+32.77%+56.74% 368.14B
Weighted average by Cap. -0.49%-3.44%+38.83%+65.89%

Financials

2026 *2027 *
Net sales 3.14B 2.71B 2.54B 2.32B 4.36B 300B 4.38B 30.09B 11.74B 151B 11.79B 11.53B 502B 3.44B 2.97B 2.78B 2.54B 4.78B 329B 4.8B 32.99B 12.87B 166B 12.92B 12.64B 551B
Net income 1.2B 1.03B 967M 883M 1.66B 114B 1.67B 11.48B 4.48B 57.77B 4.5B 4.4B 192B 1.32B 1.14B 1.06B 972M 1.83B 126B 1.84B 12.63B 4.93B 63.57B 4.95B 4.84B 211B
Net Debt -2.97B -2.56B -2.4B -2.19B -4.13B -284B -4.14B -28.49B -11.12B -143B -11.16B -10.92B -476B -3.81B -3.28B -3.07B -2.81B -5.29B -364B -5.3B -36.48B -14.23B -184B -14.29B -13.98B -609B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
28/08/26 $515.46 -2.36% 266,869
27/08/26 $527.91 +2.17% 391,005
26/08/26 $516.68 -0.36% 254,780
25/08/26 $518.53 +1.10% 876,497
24/08/26 $512.88 -0.05% 323,887
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
515.46USD
Average target price
664.33USD
Spread / Average Target
+28.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock